Is Nilotinib included in medical insurance?

Nilotinib (Nilotinib), which is marketed in China, has entered the category of Class B medical insurance through the relevant policies of the National Medical Insurance Administration. The general name is nilotinib, but reimbursement is limited to patients who meet the indications, including newly diagnosed Philadelphia chromosome-positive patients. Adult patients with chronic myelogenous leukemia (Ph+CML) and pediatric patients over 2 years old in the chronic phase; and adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in the chronic phase or accelerated phase who are resistant or intolerant to previous treatments (including imatinib) and pediatric patients over 2 years old in the chronic phase.

Nilotinib belongs to a group of targeted therapy drugs called tyrosine kinase inhibitors (TKIs), which are used to treat cancers in which cancer cells have certain changes in their genes. These cancer cells have an abnormal gene called the BCR-ABL-1 gene. The BCR-ABL-1 gene produces high levels of a substance called tyrosine kinase (TK). Tyrosine kinases stimulate cancer cells to grow and divide. Nilotinib works by turning off (inhibiting) tyrosine kinases.

The specifications of the original drug Nilotinib marketed in ChinaThe price of 150mg*120 capsules per box may be around 9,000 yuan, and patients must purchase and use it under the guidance of a doctor with a prescription. The Indian version of the original drug Nilotinib sold overseas may cost around 1,000 yuan per box of 150mg*28 capsules (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. There is currently no generic version of Nilotinib on the market. For more drug information and specific prices, please consult a medical consultant.